SB-742457

SB-742457 is a drug that was under development by GlaxoSmithKline for the treatment of Alzheimer's disease. It acts as a 5-HT6 receptor antagonist. The development was discontinued after phase II clinical trials.

Development[edit | edit source]

GlaxoSmithKline initiated the development of SB-742457 as a potential treatment for Alzheimer's disease. The drug is a 5-HT6 receptor antagonist, which means it blocks the action of the 5-HT6 receptor. This receptor is involved in the regulation of various brain functions, including memory and learning, which are impaired in Alzheimer's disease.

The development of SB-742457 reached phase II clinical trials. However, the trials did not show sufficient efficacy of the drug in improving cognitive function in patients with Alzheimer's disease. As a result, GlaxoSmithKline decided to discontinue the development of SB-742457.

Mechanism of Action[edit | edit source]

SB-742457 is a 5-HT6 receptor antagonist. The 5-HT6 receptor is a subtype of the 5-HT receptor, which is activated by the neurotransmitter serotonin. By blocking the action of the 5-HT6 receptor, SB-742457 is thought to enhance the release of acetylcholine, a neurotransmitter that is crucial for memory and learning.

Clinical Trials[edit | edit source]

The development of SB-742457 reached phase II clinical trials. These trials are designed to assess the efficacy and safety of a drug in a larger group of patients. However, the results of the phase II trials for SB-742457 did not show a significant improvement in cognitive function in patients with Alzheimer's disease. Therefore, the development of the drug was discontinued.

See Also[edit | edit source]

SB-742457 Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.